Operating Partners
Shore operating partners bridge the financial expertise of Shore investment professionals with the operating and strategic needs of our portfolio companies. With more than 240 years of healthcare experience, Shore operating partners facilitate the implementation of value creation strategies through past experience and a deep network of industry relationships.
Kevin Johnson, ClearPath Diagnostics Board of Directors Member
Kevin Johnson currently serves on the ClearPath Diagnostics Board of Directors and has over 26 years of experience in the lab diagnostics industry. From 1996 until 2003, Kevin served as Chairman, Chief Executive Officer and President of DIANON Systems, Inc., a publicly-traded cancer diagnostic services company. During that time, DIANON grew annual revenues from approximately $56 million to approximately $200 million, and the company's market capitalization grew from $45 million to approximately $600 million when it was sold to Laboratory Corporation of America (NYSE: LH) in January of 2003. Prior to joining DIANON, Mr. Johnson was employed by Quest Diagnostics and Quest's predecessor, the Life Sciences Division of Corning, Inc., for 18 years, and held numerous management and executive level positions.
Kevin is also currently a member of the Board of Precision Therapeutics, a diagnostics services company which measure patient's tumor sensitivity and resistance to a range of therapeutic alternatives under consideration. He continues to serve on the Board of NeoGenomics, Inc., which operates a network of cancer-focused testing laboratories.
Mr. Johnson received a Bachelor of science degree in Business Administration from St. John's University.
